Results 171 to 180 of about 2,023,245 (348)
COMBINED DRUG TREATMENT OF TUBERCULOSIS. III. CLINICAL APPLICATION OF THE PRINCIPLES OF APPROPRIATE AND ADEQUATE CHEMOTHERAPY TO THE TREATMENT OF PULMONARY TUBERCULOSIS [PDF]
William F. Russell +4 more
openalex +1 more source
Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior +5 more
wiley +1 more source
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel +9 more
wiley +1 more source
Patterns and Factors Associated with Podiatry Service Use Among Colorectal Cancer Patients Following Chemotherapy in South Australia: Focus on Chemotherapy-Induced Peripheral Neuropathy (CIPN). [PDF]
Dars S +5 more
europepmc +1 more source
Local chemotherapy of experimentally tumor-seeded wounds [PDF]
Arthur G. Ship +2 more
openalex +1 more source
Nasopharyngeal Carcinoma: Chemotherapy or No Chemotherapy? [PDF]
openaire +3 more sources
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee +3 more
wiley +1 more source
Age-related differences in adjuvant chemotherapy use and outcomes in stage II colon cancer: a retrospective cohort study. [PDF]
Zhou Q +5 more
europepmc +1 more source

